+

WO2008011700A1 - Compositions et procédés permettant d'atténuer les douleurs articulaires et d'améliorer la souplesse articulaire - Google Patents

Compositions et procédés permettant d'atténuer les douleurs articulaires et d'améliorer la souplesse articulaire Download PDF

Info

Publication number
WO2008011700A1
WO2008011700A1 PCT/CA2006/001244 CA2006001244W WO2008011700A1 WO 2008011700 A1 WO2008011700 A1 WO 2008011700A1 CA 2006001244 W CA2006001244 W CA 2006001244W WO 2008011700 A1 WO2008011700 A1 WO 2008011700A1
Authority
WO
WIPO (PCT)
Prior art keywords
nutritional supplement
joint
administering
individual
pain
Prior art date
Application number
PCT/CA2006/001244
Other languages
English (en)
Other versions
WO2008011700A8 (fr
Inventor
Marvin Heuer
Shan Chaudhuri
Ken Clement
Original Assignee
Iomedix Joint International Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iomedix Joint International Srl filed Critical Iomedix Joint International Srl
Priority to PCT/CA2006/001244 priority Critical patent/WO2008011700A1/fr
Publication of WO2008011700A1 publication Critical patent/WO2008011700A1/fr
Publication of WO2008011700A8 publication Critical patent/WO2008011700A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum

Definitions

  • the present invention relates to a nutritional composition for alleviating pain in the joints, restoring joint flexibility and supporting healthy joint function in an individual, e.g., a human or animal.
  • the present invention provides for a nutritional supplement directed towards alleviating joint pain quickly in an effective formulation.
  • the nutritional supplement of the present invention also provides long-lasting relief from joint pain and helps to restore joint flexibility.
  • Said nutritional supplement of the present invention comprises at least Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides, e.g., MicroLactinTM and source of Curcuminoids.
  • the present invention may be effective in alleviating joint pain by reducing tight junction permeability as well as inducing a reduction in inflammamation by reducing histamine levels, thus inhibiting vasodilation and permeability of blood vessels at the site of injury.
  • the present invention is directed towards a nutritional supplement which may, for example, quickly alleviate joint pain and provide long-lasting relief from joint pain as well as help to restore joint flexibility.
  • the present invention may also be effective in ameliorating the preceding indication by providing a reduction in tight junction permeability leading to a reduction in neutrophil infiltration at the site of injury, a reduction of histamine levels, inhibition of Bradykinin leading to less stimulation of the pain and inflammation pathways, helping to prevent the onset of arthritis, improvement in cell membrane integrity, improvement in joint lubrication, inhibition of pro-inflammatory cytokines as well as providing a source of antioxidants.
  • the present invention may include the use of a combination, wherein said combination comprises one or more of, without being limited to, Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides, e.g., MicrolactinTM, a source of Curcuminoids, Bromelain-powder Extract, a source of Epigallocatechin Gallates, Alpha Lipoic Acid, a source of Resveratrol, a source of Esterified Fatty Acid Carbons, a source of casein, and a multimineral joint complex.
  • the supplement dosage may be consumed in any form, e.g., a capsule, a tablet, a caplet, a liquid beverage, a powder beverage mix or as a dietary gel.
  • the preferred dosage of the present embodiment is as a caplet.
  • the dosage form of the nutritional supplement in accordance with the aforementioned embodiment or further embodiments as interpreted by one of skill in the art related to the present invention may be provided in accordance with customary processing techniques for herbal and/or dietary or nutritional supplements in any of the forms mentioned above.
  • said nutritional supplement is provided in a timed-release oral mode of delivery.
  • the present invention may be employed to alleviate joint pain and provide long-lasting relief therefrom while concomitantly improving joint flexibility.
  • the nutritional supplement of the present invention may be of particular interest to those seeking to improve joint function as a result of inflammation as well as relieving the pain associated with joint inflammation.
  • the amount of the composition administered an individual e.g. a human or an animal, may vary depending upon, e.g., the desired effect, the size of the person, the individual characteristics of the individual, and other such factors.
  • the presented and various other envisioned embodiments of the composition of the present invention may be administered to the diet of a person on a daily basis as needed to ameliorate joint inflammation and the associated pain.
  • Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides, e.g., MicroLactinTM, is a natural ingredient derived from concentrated milk proteins wherein the key constituent provides fast, effective pain relief and improves joint function related to everyday activities (including reduced stiffness and increased flexibility), while promoting joint health (Zenk JL, Helmer TR, Kuskowskl, MA.
  • Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides, e.g., MicroLactinTM supplementation was found to be significantly more effective than glucosamine alone over a 6 week period in alleviating joint pain and ameliorating joint physical functioning and stiffness.
  • the WOMAC Criteria consist of the following: walking stairs, getting up from a seated position, standing, bending to the floor, walking, getting in and out of a car, shopping, putting on or taking off socks, turning over in bed, sitting, getting on and off the toilet, heavy and light domestic duties, general work activities, sitting cross-legged, cycling, driving and praying.
  • Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides, e.g., MicroLactinTM, may further comprise cholesterol and blood-pressure lowering (Sharpe SJ, Gamble GD, Sharpe DN. Cholesterol- lowering and blood pressure effects of immune milk. Am J Clin Nutr. 1994;59:929-934.).
  • Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides, e.g., MicroLactinTM , is thought to act by decreasing inflammation in joints via a reduction in tight junction permeability (Ormord D. J., Miller T. E. A low molecular weight component derived from the milk of yper immunized cows suppresses inflammation by inhibiting neutrophil emigration. Agents & Actions 1992;35:1-10.). This, in turn, inhibits neutrophil migration from blood vessels into the vascular space within joints (Stelwagen K., Ormord D.J. An anti-inflammatory component derived from milk of hyperimmunized cows reduces tight junction permeability in vitro.
  • Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides, e.g., MicroLactinTM acts to restore the protective capillary barrier around joints (Zenk JL, Helmer TR, Kuskowskl, MA. The Effects of Milk Protein Concentrate on the Symptoms of Osteoarthritis in Adults: An Exploratory, Randomized, Double- Blind, Placebo-Controlled Trial. Curr Ther Res 2002 ;63(7).).
  • One aspect of the present invention includes the use of IgG Hyperimmune micronutrient milk anti-inflammatory peptides.
  • IgG Hyperimmune micronutrient milk anti-inflammatory peptides For example, U.S. Patent Nos. 4,284,623, 4,956,349, 5,194,255, 5,242,691 , 5,352,462, 5,650,175, and 5,980,953 disclose methods and processes related to the extraction and use of said IgG Hyperimmune micronutrient milk anti-inflammatory peptides.
  • U.S. Patent No. 4,284,623 purports to describe a process for producing an anti-inflammatory milk and further discloses a method for treating inflammation in animals.
  • the patent purports to describe a process of immunizing a bovid involving the steps of antigen selection, sensitization of the bovid by primary immunization, testing the serum of the bovid to confirm sensitivity induction, administering boosters of the appropriate dosage to induce and maintain an antiinflammatory factor-producing state, testing the properties of the milk and collecting milk from the bovid during the anti-inflammatory factor-producing state.
  • 4,956,349 purports to describe a method of producing an anti-inflammatory factor from bovid milk by maintaining the animal in a hyperimmunized state using a polyvalent mixture of bacterial antigens. Further, the patent suggests a method of treating inflammation in an animal which comprises administering to the animal an anti-inflammatorily effective amount of the anti-inflammatory factor termed "Milk Anti-Inflammatory Factor (MAIF)".
  • MAIF Milk Anti-Inflammatory Factor
  • U.S. Patent No. 5,194,255 purport to describe a method for reducing elevated arterial blood pressure in an animal utilizing an anti-hypertensive factor from hypehmmunized milk.
  • the bovid from which the Hyperimmune milk is obtained is immunized using a heat-killed polyvalent bacterial liquid vaccine.
  • U.S. Patent No. 5,242,691 purports to describe a method and use of the isolation of an anti-inflammatory composition from hyperimmunized milk.
  • the anti-inflammatory composition is produced by a process involving the following steps of: removing the fat from milk of a milk-producing animal to produce skimmed milk, pasteurizing the skimmed milk, removing casein from the resultant milk, removing the whey macromolecules with a weight greater than 10,000 Daltons, reducing the ionic strength of the composition to produce an aggregate with anti-inflammatory activity wherein the aggregate has a molecular weight of less than 5,000 Daltons, removing from the composition the macromolecules having a weight less than about 5,000 Daltons, and collecting the composition.
  • the patent also purports to describe a method of inhibiting a cellular inflammatory response by administering to an animal the anti-inflammatory composition.
  • U.S. Patent No. 5,352,462 purports to describe a method for using antiinflammatory milk to prevent interaction between CD18 cell-surface antigens and other molecules where these interactions are known to be necessary for cells to exit the vasculature and that such an emigration leads to increased tissue damage in animals during the inflammatory response.
  • the invention also claims the use of the anti-inflammatory factor in mammals to prevent the emigration of cells from the vasculature and to suppress the mitogenic response of lymphocytes to foreign antigens.
  • This patent also purports to describe a method for detaching neutrophils which have attached to endothelial cells in a mammal using the anti-inflammatory factor.
  • U.S. Patent No. 5,650,175 purports to describe a use of anti-inflammatory factor present in milk purified by filtering to remove molecules with weight greater than 10,000 Daltons, fractionating the filtrate by ion-exchange, gel filtration and affinity chromatography.
  • the purported invention is also directed towards a method for using milk anti-inflammatory factor to prevent neutrophils from adhering to the endothelium of venules or to detach neutrophils which have already adhered to the endothelial cells lining the walls of the venules, thereby reducing the tissue damage associated with the inflammatory response.
  • U.S. Patent No. 5,980,953 purports to describe additional methods for purifying an anti-inflammatory factor from skimmed milk involving the following steps of: ultra-filtering skimmed milk through a filter with a molecular weight cutoff of 1 ,000 Daltons, collecting the less than 1 ,000 Dalton permeate, extracting the permeate by organic partition extraction and obtaining the organic extract from the extraction, separating the organic extract by reverse-phase HPLC chromatography and collecting the eluate.
  • the patent also purports to describe methods for inhibiting neutrophil adherence and detaching neutrophils from endothelial walls, inhibiting CD18 interactions, inhibiting the emigration of leukocytes, inhibiting an inflammatory response, and suppressing the mitogenic response of lymphocytes in a host mammal to foreign antigens.
  • the nutritional supplement may include Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides.
  • a serving of the nutritional supplement may include from about 1 mg to about 10 g of Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides.
  • the preferred dosage of a serving of the nutritional supplement comprises about 2.000 g of Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides.
  • Curcumin is the active compound of tumeric (Curcumin longa), which is a key ingredient in many curries. Curcumin, when used to treat post-surgical inflammation, has been shown to be superior to some traditional medications (Satoskar RR, Shah SJ, Shenoy SG. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 1986; 24, 651-654). Additionally, in mice, it has been shown to offer a potential treatment with respect to neuropathic pain by acting through the inhibition of nitric oxide (NO) and tumor necrosis factor-alpha (TNF ⁇ ) (Sameer Sharma, Srinivas K.
  • NO nitric oxide
  • TNF ⁇ tumor necrosis factor-alpha
  • Curcuminoids have furthermore been shown to protect against free radical damage via their action as a potent antioxidants (Sreejayan N, Rao MNA. Free radical scavenging activity of curcuminoids. Arzneistoffforschung, 1996; 46, 169-171.) and they are also able to reduce inflammation through the reduction of circulating histamine levels (Arora RB, Basu N, Kapoor V, Jain AP. Anti-inflammatory studies on Curcuma longa (turmeric). Indian Journal of Medical Research, 1971 ; 59, 1289-1295).
  • the nutritional supplement may include Curcumin.
  • a serving of the nutritional supplement may include from about 1 mg to about 1 g of Curcumin.
  • the preferred dosage of a serving of the nutritional supplement comprises about 0.005 g of Curcumin.
  • Bromelain is a proteolytic enzyme found in pineapple which has been shown to be an effective anti-inflammatory agent in rats, even when compared to prednisone (Uhlig G, Seifert J. The effect of proteolytic enzymes (traumanase) on posttraumatic edema. Fortschr Med 1981 ;99:554-556, Vellini M, Desideri D, Milanese A, et al. Possible involvement of eicosanoids in the pharmacological action of bromelain. Arzneiffenbachforschung 1986;36:110-112), a conventional steroidal anti-inflammatory. It is often used as a digestive aid as well as to reduce tissue and muscular inflammation.
  • Bromelain The action of Bromelain has been evidenced to be due to its inhibitory action on Bradykinin, a stimulator of pain and inflammation (Kumakura S, Yamashita M, Tsurufuji S. Effect of bromelain on kaolin-induced inflammation in rats. Eur J Pharmacol 1988; 150:295-301 ). In rats, Bromelain also has been shown to stimulate the conversion of plasminogen to plasmin which in turn increases venous permeability and thus aiding in drainage, thereby facilitating anti-inflammatory action (Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 1988;22:191-203).
  • Bromelain supplementation results in a drastic reduction in swelling in boxers as compared to placebo (Blonstein JL. Control of swelling in boxing injuries. Practitioner 1960;185:78).
  • supplementation resulted in greatly improved post-surgical recovery in terms of pain and swelling (Tassman GC, Zafran JN, Zayon GM. Evaluation of a plant proteolytic enzyme for the control of inflammation and pain. J Dent Med 1964;19:73-77.).
  • Bromelain has been shown to benefit the recovery of blunt musculoskeletal injuries in all 4 parameters of: swelling, pain at rest and during movement, and tenderness, examined in an additional study (Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. Fortschr Med 1995;113:303-306).
  • the nutritional supplement may include Bromelain- powder Extract.
  • a serving of the nutritional supplement may include from about 1 mg to about 1 g of Bromelain-powder Extract.
  • the preferred dosage of a serving of the nutritional supplement comprises about 0.001 g of Bromelain-powder Extract.
  • Epigallocatechin Gallate is the most active Catechin in Green Tea (Camellia sinensis) leaf and is mainly used as a weight loss agent.
  • Green tea has been shown to reduce total cholesterol levels (Kono S, Shinchi K, lkeda N. Green tea consumption and serum ipid profiles: A cross- sectional study in Northern Kyushu, Japan. Preventive Medicine, 1992; 21 , 526- 531.) and to promote fat reduction as well as increase energy expenditure in humans (Dulloo, A. G. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. American Journal of Clinical Nutrition, 1999; 70, 1040-1045.; Chantre P, Lairon D. Recent findings of green tea extract R25 (Exolise) and its activity for the treatment of obesity.
  • the nutritional supplement may include Green Dry Leaf Extract.
  • a serving of the nutritional supplement may include from about 1 mg to about 1 g of Green Dry Leaf Extract.
  • the preferred dosage of a serving of the nutritional supplement comprises about 0.001 g of Green Dry Leaf Extract.
  • Alpha Lipoic Acid (ALA) is set forth in greater detail in Example 1 below.
  • Alpha Lipoic Acid also commonly known as 6,8-thioctic acid is both a water- and fat-soluble enzyme found in mitochondria. It possesses strong antioxidant activity.
  • ALA supplementation has been shown to increase glucose clearance in patients with type-2 diabetes (Jacob S, Henriksen EJ, Schiemann AL, Simon I, Clancy DE, Tritschler HJ, Jung Wl, Augustin HJ, Dietze GJ. Enhancement of glucose disposal in patients with type 2 diabetes by alpha-lipoic acid. Arzneiffenbachaba, 1995; 45, 872-87.; Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K.
  • Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radical Biology and Medicine, 1999; 27, 309-314.). Moreover, its antioxidant activities (Packer L, Witt EH, and Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Rad Biol Med 1995; 19: 227-250.) have been shown to improve glucose tolerance and insulin-sensitivity in insulin-resistant obese Zucker rats (Saengsihsuwan V, Kinnick TR, Schmit MB, and Henriksen EJ. Interactions of exercise training and -lipoic acid on glucose transport in obese Zucker rats.
  • the nutritional supplement may include Alpha Lipoic Acid.
  • a serving of the nutritional supplement may include from about 1 mg to about 1 g of Alpha Lipoic Acid.
  • the preferred dosage of a serving of the nutritional supplement comprises about 0.001 g of Alpha Lipoic Acid.
  • Resveratrol found in Polygonum cuspidatum, is a natural phytoalexin produced by some plants as response to injury or fungal infections. It is found in high concentrations in grape skins and is used to prevent heart disease.
  • Resveratrol has also received attention due to its display of anti-cancer properties (Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM.. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997; 275:218-220.) which may be possibly acting through its action as a potent antioxidant (Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?
  • Resveratrol has additionally been shown to inhibit smooth muscle cell proliferation (Zou J, Huang Y, Chen Q, et al. Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells, lnt J Oncol.
  • Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. J Vase Surg. 2005 Dec;42(6):1190-7.), which is a factor considered necessary for arterial plaque formation again, possibly acting towards the prevention of heart disease. Resveratrol has further been shown to induce CYP1A1 enzyme activity, which is known to protect against disease and oxidative stress (Ciolino HP, Yeh GC. Inhibition of aryl hydrocarbon-induced cytochrome P450 1A1 enzyme activity and CYP1A1 expression by resveratrol. MoI Pharmacol. 1999; 56:760-767.).
  • the nutritional supplement may include Polygonum Cuspidatum-Powder Extract.
  • a serving of the nutritional supplement may include from about 1 mg to about 1 g of Polygonum Cuspidatum-Powder Extract.
  • the preferred dosage of a serving of the nutritional supplement comprises about 0.001 g of Polygonum Cuspidatum-Powder Extract.
  • Esterified Fatty Acid Carbons e.g. Celadrin
  • Esterified fatty acid carbons are naturally occurring fatty acids used to promote cardiovascular and joint health.
  • the nutritional supplement may include Esterified Fatty Acid Carbons, e.g., Celadrin.
  • a serving of the nutritional supplement may include from about 1 mg to about 1 g of Esterified Fatty Acid Carbons e.g., Celadrin.
  • the preferred dosage of a serving of the nutritional supplement comprises about 0.001 g of Esterified Fatty Acid Carbons, e.g., Celadrin.
  • the C12 Casein-derived natural milk-derived protein is used in methods of controlling blood pressure.
  • the nutritional supplement may include Casein (C-12 Peptide).
  • a serving of the nutritional supplement may include from about 1 mg to about 1 g of Casein (C-12 Peptide).
  • the preferred dosage of a serving of the nutritional supplement comprises about 0.001 g Casein (C-12 Peptide).
  • Multimineral joint complex In a recent randomized control trial, it was suggested that supplementation with a mulitmineral joint complex can improve joint health and function within 1-2 weeks (Miller MJ, Mehta K, Kunte S, Raut V, Gala J, Dhumale R, Shukla A, Tupalli H, Parikh H, Bobrowski P, Chaudhary J.
  • the nutritional supplement may include a naturally- occurring mineral composite, e.g., SierraSilTM joint complex.
  • a serving of the nutritional supplement may include from about 1 mg to about 1 g of a multimineral joint complex.
  • the preferred dosage of a serving of the nutritional supplement comprises about 0.001 g of a naturally-occurring mineral composite, e.g., SierraSilTM joint complex.
  • the present invention provides a method which includes the step of consuming a composition, wherein the method may lead to quick alleviation of joint pain and provide long-lasting relief from joint pain as well as help to restore joint flexibility via a reduction in inflammation.
  • the present invention may additionally provide via execution of the method sources of antioxidants.
  • the method includes the step of consuming a nutritional supplement which reduces inflammation thereby ameliorating joint function as well as providing a source of antioxidants.
  • the method includes the daily consumption of a combination wherein the combination includes one or more of, without being limited to, IgG Hyperimmune micronutrient peptides i.e., MicrolactinTM, a source of Curcuminoids, Bromelain-powder Extract, a source of Epigallocatechin Gallates, Alpha Lipoic Acid, a source of Resveratrol, a source of Esterified Fatty Acid Carbons, a sources of casein, and a multimineral joint complex.
  • the present nutritional supplement may be utilized in methods to quickly alleviate joint pain and provide long-lasting relief from joint pain as well as help to restore joint flexibility via a reduction in inflammation in a formulation designed to be consumed on a daily basis.
  • a dietary supplement is provided in two servings per day as caplets.
  • the formulation comprises Milk Protein Concentrate comprising IgG Hyperimmune micronutrient peptides, e.g., MicrolactinTM, (2.000 g), Curcumin Longa-Powder Extract (0.005 g) standardized to 95% Curcuminoids, Bromelain-powder Extract (0.001 g), Green Tea Dry Leaf Extract (0.001 g) standardized to 45% EGCG, Alpha Lipoic Acid (0.001 g), Polygonum Cuspidatum-Powder Extract (0.001 g) standardized to 50% Resveratrol, Esterified Fatty Acid Carbons (0.001 g)(Celadrin), Casein as a source of C-12 peptide (0.001 g), and a naturally- occurring mineral composite, e.g., SierraSilTM, joint complex (0.001 g).
  • IgG Hyperimmune micronutrient peptides e.g., MicrolactinTM, (
  • each two caplet serving may be consumed with each meal, e.g., breakfast, lunch and dinner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition et un procédé d'administration d'un supplément nutritif à un individu, par exemple, un être humain ou un animal, pour atténuer les douleurs articulaires, soulager de manière prolongée les douleurs articulaires, améliorer le fonctionnement articulaire, ainsi qu'aider à retrouver de la souplesse articulaire par le biais d'une diminution de l'inflammation. Le supplément nutritif peut comprendre au moins un concentré de protéines de lait comprenant des peptides de micronutriments d'IgG Hyperimmune et une source de curcuminoïdes. Le supplément nutritif peut être consommé au moins une fois par jour.
PCT/CA2006/001244 2006-07-28 2006-07-28 Compositions et procédés permettant d'atténuer les douleurs articulaires et d'améliorer la souplesse articulaire WO2008011700A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CA2006/001244 WO2008011700A1 (fr) 2006-07-28 2006-07-28 Compositions et procédés permettant d'atténuer les douleurs articulaires et d'améliorer la souplesse articulaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2006/001244 WO2008011700A1 (fr) 2006-07-28 2006-07-28 Compositions et procédés permettant d'atténuer les douleurs articulaires et d'améliorer la souplesse articulaire

Publications (2)

Publication Number Publication Date
WO2008011700A1 true WO2008011700A1 (fr) 2008-01-31
WO2008011700A8 WO2008011700A8 (fr) 2008-07-10

Family

ID=38981079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/001244 WO2008011700A1 (fr) 2006-07-28 2006-07-28 Compositions et procédés permettant d'atténuer les douleurs articulaires et d'améliorer la souplesse articulaire

Country Status (1)

Country Link
WO (1) WO2008011700A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041142A3 (fr) * 2006-10-06 2008-09-12 Gianluca Mech Complément alimentaire avec activateur de protéines
WO2010025335A2 (fr) * 2008-08-29 2010-03-04 Dr Pepper/Seven Up, Inc. Compositions fonctionnelles consommables favorisant la santé de la peau et leurs procédés d'utilisation
CN116076365A (zh) * 2023-02-17 2023-05-09 贵州省林业学校(贵州省林业干部学校) 一种威宁短柱油茶穗条的快繁方法
EP4186497A1 (fr) * 2021-11-26 2023-05-31 Dorian Bevec Acide alpha lipoïque, epigallocatéchin-3-gallate,curcumine comme médicament pour le traitement de l'arthrose pour le l'traitment ou d'une infection sars-cov-2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002071857A1 (fr) * 2001-03-12 2002-09-19 Bristol-Myers Squibb Company Compositions de confiserie contenant une ou plusieurs fibre(s)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002071857A1 (fr) * 2001-03-12 2002-09-19 Bristol-Myers Squibb Company Compositions de confiserie contenant une ou plusieurs fibre(s)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AMEYE L.G. ET AL.: "Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence", ARTHRITIS RESEARCH & THERAPY, vol. 8, no. R127, 19 July 2006 (2006-07-19), pages 1 - 22 *
ARORA R.B. ET AL.: "Anti-inflammatory studies on curcuma longea (turmeric)", INDIAN JOURNAL OF MEDICAL RESEARCH, vol. 59, no. 8, August 1971 (1971-08-01), pages 1289 - 1295 *
BURKITT M.J. ET AL.: "Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 381, no. 2, 15 September 2000 (2000-09-15), pages 253 - 263 *
HAQQI T.M. ET AL.: "Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 96, 1999, pages 4524 - 4529 *
HESSLINK R. ET AL.: "Cetylated fatty acids improve knee function in patients with osteoarthritis", THE JOURNAL OF RHEUMATOLOGY, vol. 29, no. 8, 2002, pages 1708 - 1712 *
PACKER L. ET AL.: "Alpha-lipoic acid as a biological antioxidant", FREE RADICAL BIOLOGY AND MEDICINE, vol. 19, no. 2, 1995, pages 227 - 250 *
TOWNSEND R.R. ET AL.: "A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension", AMERICAN JOURNAL OF HYPERTENSION, vol. 17, no. 11, 2004, pages 1056 - 1058 *
YUAN G. ET AL.: "Natural products and anti-inflammatory activity", ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, vol. 15, no. 2, June 2006 (2006-06-01), pages 143 - 152 *
ZENK J.L. ET AL.: "The effects of milk protein concentrate on the symptoms of osteoarthritis in adults: an exploratory, randomized, double-blind, placebo-controlled trial", CURRENT THERAPEUTIC RESEARCH, vol. 63, no. 7, July 2002 (2002-07-01), pages 430 - 442 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008041142A3 (fr) * 2006-10-06 2008-09-12 Gianluca Mech Complément alimentaire avec activateur de protéines
US8557303B2 (en) 2006-10-06 2013-10-15 Gianluca Mech Dietary supplement with protein activator
US9144592B2 (en) 2006-10-06 2015-09-29 Gianluca Mech Dietary supplement with protein activator
WO2010025335A2 (fr) * 2008-08-29 2010-03-04 Dr Pepper/Seven Up, Inc. Compositions fonctionnelles consommables favorisant la santé de la peau et leurs procédés d'utilisation
WO2010025335A3 (fr) * 2008-08-29 2010-05-20 Dr Pepper/Seven Up, Inc. Compositions fonctionnelles consommables favorisant la santé de la peau et leurs procédés d'utilisation
EP4186497A1 (fr) * 2021-11-26 2023-05-31 Dorian Bevec Acide alpha lipoïque, epigallocatéchin-3-gallate,curcumine comme médicament pour le traitement de l'arthrose pour le l'traitment ou d'une infection sars-cov-2
CN116076365A (zh) * 2023-02-17 2023-05-09 贵州省林业学校(贵州省林业干部学校) 一种威宁短柱油茶穗条的快繁方法
CN116076365B (zh) * 2023-02-17 2023-11-14 贵州省林业学校(贵州省林业干部学校) 一种威宁短柱油茶穗条的快繁方法

Also Published As

Publication number Publication date
WO2008011700A8 (fr) 2008-07-10

Similar Documents

Publication Publication Date Title
AU2017312737B2 (en) Vascular calcification and cardiovascular/associated diseases prevention and treatment
AU2008339944B2 (en) Preparations with rosehip extracts, and method of producing rosehip extracts
JP2002501030A5 (fr)
WO2002056899A1 (fr) Compositions et procedes pour reduire les oxysterols dans le sang
KR101285234B1 (ko) 백미 추출물을 포함하는 관절염 예방 및 치료용 조성물
US20020192314A1 (en) Dietary supplement compositions
US20080026983A1 (en) Compositions and methods for alleviating joint pain and improving joint flexibility
JP2005527539A (ja) 黒米からのアントシアニンの抽出方法およびその組成物
Zakynthinos et al. Hippophae rhamnoides: safety and nutrition
EP1649761A1 (fr) Composition pour le traitement des insuffisances veineuses chroniques a l'aide d'un extrait de feuilles de vigne rouge
WO2008011700A1 (fr) Compositions et procédés permettant d'atténuer les douleurs articulaires et d'améliorer la souplesse articulaire
JP2009298769A (ja) 脂肪蓄積抑制用組成物
CN100376255C (zh) 具有抗炎活性和抗动脉粥样硬化活性的藿香提取物以及含有从所述提取物中分离和提纯的椴素的组合物
Lamponi et al. Evaluation of in vitro cell and blood compatibility and in vivo analgesic activity of plant-derived dietary supplements
US20100016246A1 (en) Food composition for functional foods and nutritional supplements
JP4325908B2 (ja) 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物
KR20140036966A (ko) 제주조릿대 잎을 이용한 운동수행능력향상용 조성물 또는 피로회복용 조성물
JP2002504928A (ja) Ｌｄｌの酸化を防止するための天然組成物
WO2018142328A1 (fr) Composition de traitement d'une hyperuricémie
CN104274437B (zh) A型三聚原花青素类多酚的一种药物用途
Zeeshan et al. Medicinal Importance of Ginger (Zingiber officinale): A Systematic
Skibska et al. Natural plant materials as a source of neuroprotective peptides
CA2407429C (fr) Composition pour la regulation du systeme immunitaire humain et pour la prevention et le traitement de maladies de ce systeme
KR102643099B1 (ko) 양춘사 및 백출 복합 추출물을 유효성분으로 함유하는 고지혈증 또는 동맥경화의 예방, 개선 또는 치료용 조성물
JP2019189571A (ja) 廃用性筋萎縮抑制剤及び廃用性筋萎縮抑制用食品組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06775051

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06775051

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载